Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy
Top Cited Papers
- 1 July 2015
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 276 (1), 228-232
- https://doi.org/10.1148/radiol.2015142690
Abstract
To use inductively coupled plasma mass spectroscopy (ICP-MS) to evaluate gadolinium accumulation in brain tissues, including the dentate nucleus (DN) and globus pallidus (GP), in subjects who received a gadolinium-based contrast agent (GBCA). Institutional review board approval was obtained for this study. Written informed consent for postmortem investigation was obtained either from the subject prior to his or her death or afterward from the subject's relatives. Brain tissues obtained at autopsy in five subjects who received a linear GBCA (GBCA group) and five subjects with no history of GBCA administration (non-GBCA group) were examined with ICP-MS. Formalin-fixed DN tissue, the inner segment of the GP, cerebellar white matter, the frontal lobe cortex, and frontal lobe white matter were obtained, and their gadolinium concentrations were measured. None of the subjects had received a diagnosis of severely compromised renal function (estimated glomerular filtration rate <45 mL/min/1.73 m(2)) or acute renal failure. Fisher permutation test was used to compare gadolinium concentrations between the two groups and among brain regions. Gadolinium was detected in all specimens in the GBCA agent group (mean, 0.25 µg per gram of brain tissue ± 0.44 [standard deviation]), with significantly higher concentrations in each region (P = .004 vs the non-GBCA group for all regions). In the GBCA group, the DN and GP showed significantly higher gadolinium concentrations (mean, 0.44 µg/g ± 0.63) than other regions (0.12 µg/g ± 0.16) (P = .029). Even in subjects without severe renal dysfunction, GBCA administration causes gadolinium accumulation in the brain, especially in the DN and GP.Keywords
This publication has 14 references indexed in Scilit:
- Progressive Increase of T1 Signal Intensity of the Dentate Nucleus on Unenhanced Magnetic Resonance Images Is Associated With Cumulative Doses of Intravenously Administered Gadodiamide in Patients With Normal Renal Function, Suggesting DechelationInvestigative Radiology, 2014
- High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast MaterialRadiology, 2014
- MRI contrast agents: Basic chemistry and safetyJournal of Magnetic Resonance Imaging, 2012
- Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based reviewNephrology Dialysis Transplantation, 2011
- Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosisJournal of the American Academy of Dermatology, 2011
- Biodistribution of gadolinium‐based contrast agents, including gadolinium depositionJournal of Magnetic Resonance Imaging, 2009
- Role of thermodynamic and kinetic parameters in gadolinium chelate stabilityJournal of Magnetic Resonance Imaging, 2009
- Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass SpectroscopyInvestigative Radiology, 2006
- Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission SpectroscopyInvestigative Radiology, 2004
- Safety of approved MR contrast media for intravenous injectionJournal of Magnetic Resonance Imaging, 2000